Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04641702 · ClinicalTrials.gov registry record · Phase 4

Comprehensive Esophageal Diagnostics Study

A Phase 4 study of Achalasia, sponsored by Emory University.

Recruiting
Registry status
Phase 4
Development phase
80
Enrollment target
2
Study locations

NCT04641702 is a Phase 4 study of Achalasia that is actively recruiting participants, run by Emory University. The registered enrollment target is 80 participants, below the 130-participant average among 7 other Achalasia trials with a reported enrollment target (38% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04641702, a Phase 4 study of Achalasia, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 4
Development phase
80 participants
Enrollment target
2
Study locations

Study Summary

The prospective clinical trial will study muscle fibrosis in relation to lower esophageal sphincter (LES) measurements on Functional Lumen Imaging Probe (FLIP) Topography (the novel technology that utilizes impedance planimetry) after pharmacologic challenge. A better understanding of achalasia will allow intervention at an earlier stage.

Conditions Studied

Interventions

  • DRUG Atropine challenge
  • PROCEDURE Esophageal muscle biopsy

Study Locations (2)

Georgia

  • Emory University Hospital - Atlanta
  • Emory Saint Joseph's Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2021-03-17
Est. Completion 2026-12-31
Phase Phase 4

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT04641702

The ClinicalTrials.gov registry entry for NCT04641702 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 7 other Achalasia trials with a reported enrollment target (38% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Achalasia appearing as the primary indexed condition, and to 2 interventions - of which Atropine challenge is the first listed.

NCT04641702 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT04641702 about?

NCT04641702 is a clinical study titled "Comprehensive Esophageal Diagnostics Study". The prospective clinical trial will study muscle fibrosis in relation to lower esophageal sphincter (LES) measurements on Functional Lumen Imaging Probe (FLIP) Topography (the novel technology that utilizes impedance planimetry) after pharmacologic challenge. A better understanding of achalasia will...

What is the current status of trial NCT04641702?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2021-03-17. Estimated completion is 2026-12-31.

What conditions does trial NCT04641702 study?

This clinical trial studies the following conditions: Achalasia.

What interventions are being tested in trial NCT04641702?

The interventions under investigation include: Atropine challenge (DRUG), Esophageal muscle biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT04641702?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04641702 being conducted?

This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Achalasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.